Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. XYDALBA (dalbavancine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

XYDALBA (dalbavancine)

Medicine - Posted on Jul 29 2024
Active substance (DCI)
  • dalbavancine (chlorhydrate de)
history (3)
  • 7/3/24

    XYDALBA (dalbavancin) - Antibiotic

    Summary of opinion Favourable opinion for reimbursement only in patients aged from 3 months to 17 years with acute bacterial...
    CAV :
    54321
    icône flèche
  • 12/6/23

    XYDALBA (dalbavancin) - Skin and soft tissue infections

    -
    CAV :
    54321
    icône flèche
  • 12/14/16

    XYDALBA (dalbavancin), antibiotic of the glycopeptide class

    No clinical benefit demonstrated relative to vancomycin in the management of acute bacterial skin and soft tissue infections...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • J01XA04
Manufacturer
CORREVIO
Presentation

XYDALBA 500 mg, poudre pour solution à diluer pour perfusion (code CIS : 65987568)
Flacon(s) en verre de 500 mg (CIP : 34009 550 246 0 6)

All our publications
    Bacterial infections Drug therapy Paediatrics Skin and connective tissue diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
8s2b2vp6pMCEYZpm